Trial reportAmerican journal of respiratory and critical care medicine2026
Mepolizumab efficacy in chronic obstructive pulmonary disease: insights from longitudinal patterns of blood eosinophil counts and their variability across 3 clinical trials.
Trial report in American journal of respiratory and critical care medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study MEA117106: Mepolizumab vs. Placebo as add-on Treatment for Frequently Exacerbating COPD Patients
Study MEA117113: Mepolizumab vs. Placebo as Add-on Treatment for Frequently Exacerbating COPD Patients Characterized by Eosinophil Level
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors.
Funding
Abstract
rationaleBlood eosinophil count (BEC) is a biomarker indicating type 2 inflammation in patients with chronic obstructive pulmonary disease (COPD), but can be variable.
objectivesEvaluate mepolizumab efficacy in patients with COPD with variability of BEC patterns.
methodsData were pooled from the phase 3, randomized, double-blind, placebo-controlled METREX (NCT02105948), METREO (NCT02105961), and MATINEE (NCT04133909) trials. Patients receiving mepolizumab 100 mg or placebo were included. These trials documented historical BEC (within 12 months before randomization) for all patients. Outcomes included annualized rates of moderate or severe exacerbations, and exacerbations requiring an emergency department (ED) visit and/or hospitalization. Outcomes were assessed in subgroups based on BEC values in the 12 months before randomization, at screening, and at baseline. MEASUREMENTS AND MAIN
resultsAnnualized rates of moderate or severe exacerbations were reduced, or trended toward reduction, with mepolizumab versus placebo in patients with type 2 inflammation characteristics, including those with BEC ≥300 cells/µL at any pre-randomization timepoint (21% reduction), persistently elevated BECs (12%-27% reduction), and -variable BECs over time (22%-36% reduction). Across various subgroups with elevated BEC, starting from ≥150 cells/µL, mepolizumab reduced exacerbations requiring ED visit and/or hospitalization. Patients with persistently low BEC (<150 cells/µL) experienced no benefit with mepolizumab.
conclusionsMepolizumab improved exacerbation-related outcomes in patients with COPD and type 2 inflammation, characterized by both consistently and intermittently elevated BEC. Persistent BEC elevation is not required to identify treatable eosinophilic phenotypes in COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.